Supreme Court to Hear Appeal in Bristol Myers Patent Case Against Zydus

Bristol Myers Squibb approached the Supreme Court seeking to prevent Zydus Lifesciences from manufacturing and selling a biosimilar version of its cancer drug nivolumab.

The case arose from an appeal against a Delhi High Court order that permitted Zydus to sell the biosimilar, citing public interest as the drug is life-saving.

BMS alleged patent infringement, while Zydus denied the claim and maintained that its product does not infringe existing patents. The High Court had noted that the patent is nearing expiry and allowed the biosimilar’s sale for the remaining period.

The Supreme Court will hear the appeal on February 4.